Hodgkin Lymphoma | Norton Healthcare

Indication: Hodgkin Lymphoma

A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Relapsed or Refractory patients

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: ADC Therapeutics SA

Learn more at ClinicalTrials.gov

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.